The Matrixx Zicam Verdict - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Matrixx Zicam Verdict
The authors summarize the Matrixx Initiatives, Inc. v. Siracusano case's implications for industry.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 118-122

References

1. D.G. Savage, Chic. Trib., Mar. 23, 2011; C. Bialik, Wall Street Jrnl. Apr. 1, 2011.

2. Matrixx Initiatives, Inc. v. Siracusano, 131 S. Ct. 1309 (2011) [hereinafter Matrixx].

3. Matrixx, 131 S. Ct. at 1313.

4. Id. at 1315. Zicam Cold Remedy Reportedly Accounted for Seventy Percent of Matrixx's sales. Id. at 1314.

5. Id.

6. Id. at 1317. "To prevail on their claim that Matrixx made material misrepresentations or omissions in violation of 10(b) and Rule 10b–5, respondents must prove '(1) a material misrepresentation or omission by the defendant; (2) scienter; (3) a connection between the misrepresentation or omission and the purchase or sale of a security; (4) reliance upon the misrepresentation or omission; (5) economic loss; and (6) loss causation.' " Id. at 1317 (quoting Stoneridge Investment Partners, LLC v. Scientific–Atlanta, Inc., 552 US 148, 157 [2008]).

7. 220 F.3d 36 (2d. Cir.1998).

8. Id.

9. Siracusano v. Matrixx Initiatives, Inc., No. CV 04 0886 PHX MHM, 2005 WL 3970117, *5 (D. Ariz., Dec 15, 2005).

10. Id. at *1.

11. Id.

12. Id. at *7.

13. Siracusano v. Matrixx Initiatives, Inc., 585 F.3d 1167, 1178 (9th Cir. 2009) [hereinafter Siracusano].

14. Basic Inc. v. Levinson, 485 U.S. 224, 236 (1988).

15. TSC Industries, Inc. v. Northway, Inc., 426 U.S. 438, 449, (1976).

16. Siracusano, 585 F.3d at 1178.

17. Id. at 1183.

18. Matrixx, 131 S. Ct. at 1313.

19. Id. at 1319.

20. Id.

21. Id.

22. Id. at 1321–22.

23. Id. at 1318.

24. Wyeth v. Levine, 129 S. Ct. 1187 (2009).

25. Levine v. Wyeth, 944 A.2d 179, 182 (Vt. 2006).

26. U.S. Const. art. VI.

27. Wyeth, 129 S. Ct. at 1193.

28. Id. at 1193-94.

29. FDA allows manufacturers to "add or strengthen a contraindication, warning, precaution or adverse reaction" in order to increase the safety of the product through use of a "changes being effected" (CBE) supplement. 21 CFR 314.70(c) (6) (iii) (A), (C).

30. Wyeth, 129 S. Ct. at 1197.

31. Id. at 1197–98.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here